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Kenneth Ouriel, MD, Cleveland, Ohio
Thoracoabdominal aneurysm (TAA) repair commonly
requires the administration of large quantities of blood
products. Given the coagulopathic state that may result
from proximal aortic cross clamping,1 repair of a TAA
without the availability of blood products potentially could
be catastrophic. The following report describes our periop-
erative approach to the repair of a 5.7-cm, type 3 TAA in a
21-year-old female Jehovah’s Witness.
CASE REPORT
A 21-year-old female Jehovah’s Witness was referred to us
with an asymptomatic, 5.7-cm type 3 TAA. The patient underwent
a homograft aortic valve and root replacement 6 months previ-
ously, along with repair of a 6.0-cm ascending aortic aneurysm.
Medical history included ligation of a patent ductus arteriosus at 4
years of age, pulmonary hypertension, and asthma. In addition,
before the aortic valve repair, the patient needed hospital admis-
sion for treatment of congestive heart failure.
The patient underwent extensive testing to rule out a collagen
deficiency disorder. Tissue taken at the time of the ascending aortic
aneurysm repair showed cystic medial necrosis, but no other
pathologic diagnosis was established. Because of religious beliefs,
the patient refused the administration of all allogeneic blood
products but agreed to accept cell salvage blood replacement as
long as the blood was maintained in continuous circuit with her
body.
Before surgery, the patient received 3 months of oral iron
supplementation and 3 months of subcutaneous erythropoietin.
The hemoglobin level increased from 11.5 to 15.3 g/dL over this
time. The platelet count was 239,000 uL, with an international
ratio of 0.90 and an activated partial thrombolastin time of 28.8
seconds.
At the time of surgery, the patient underwent normovolemic
hemodilution. Whole blood (2700 mL) was withdrawn into the
cell salvage circuitry (Figure) and replaced acutely with 2000 mL of
hetastarch in lactated Ringers solution and then with an ongoing
infusion of colloid. This represented 30 mL/kg of body weight.
The whole blood then was processed to produce 1400 mL of
packed red blood cells, 1000 mL of platelet poor plasma, and 300
mL of platelet rich plasma.
The patient underwent a standard type 3 TAAA repair. The
thoracic and abdominal aorta were exposed through an eighth
intercostal thoracoretroperitoneal approach. A significant degree
of periaortitis and inflammation was encountered around the an-
eurysm. Meticulous hemostasis was maintained at all times, and the
use of heparin was avoided.
Repair of the aneurysm proceeded uneventfully, with replace-
ment of the lower thoracic and abdominal aorta with an 18-mm
Dacron graft (Boston Scientific, Natick, Mass). Before placement
of the graft, an 8-mm side limb was first anatamosed to the
proximal portion of the graft and then anastomosed end to side to
the left common iliac artery.2 Next, a distal aortic clamp was
placed, followed by sewing of the proximal anastamosis. On release
of the proximal aortic clamp, the lower extremities, pelvis, and hind
gut were perfused during performance of the visceral/renal and
distal aortic anastomoses. The visceral and renal vessels were anas-
tomosed to the graft as a visceral patch, and the lumbar vessels were
oversewn. No intercostal vessels required reimplantation. A seg-
ment of aneurysmal aortic wall was excised for pathologic exami-
nation. The patient was kept normothermic throughout. Total
blood loss was was estimated to be 2300 mL. The red blood cells
were salvaged in a cell saver and then reinfused along with the
previously withdrawn red blood cells. At the conclusion of the case,
the platelet-poor and platelet-rich plasmas were reinfused. Intra-
venous 1-deamino-8-d-arginine vasopression was also adminis-
tered.
At day 1 after surgery, the patient had a hemoglobin level of
9.8 g/dL, a platelet count of 125,000 uL, an international ratio of
1.19, and an activated partial thrombolastin time of 44.2 seconds.
Histologic examination of the aortic wall revealed giant cell arteri-
tis. The patient had an uneventful postoperative course and was
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discharged home on postoperative day 8, continued on oral iron
supplementation, and remains well at the 1.5-year follow-up.
DISCUSSION
The surgical treatment of patients who refuse the ad-
ministration of allogeneic blood products provides a special
challenge to the surgeon.3 This is particularly true in oper-
ations where a reasonable amount of blood loss can be
expected and where coagulopathy is frequently encoun-
tered. TAA repair is an operation that typifies both of these
situations.
Our approach to the avoidance of allogeneic blood
products in this patient had three phases. First, the patient
was optimized with respect to blood count and coagulation
function before surgery. Second, intraoperative blood loss
was kept to a minimum, with normovolemic hemodilution
and the replacement of lost red blood cells with cell salvage.
Last, restoration of blood count was facilitated with the
help of postoperative iron supplementation.
Erythropoietin is a glycoprotein hormone normally
produced in response to tissue hypoxia. Its function is to
increase circulating red cell mass.4,5 The use of recombi-
nent human erythropoietin is well described in the manage-
ment of anemia in hemodialysis patients,6 however its use
in surgical patients has not been well explored. Our pa-
tient’s increase in preoperative hemoglobin level from 11.5
to 15.3, largely in response to 3 months of treatment with
erythropoietin, undoubtedly contributed to the satisfactory
postoperative hemoglobin level of 9.8 g/dL. The ability to
increase the preoperative hemoglobin to the upper end of
normal also contributed to the success of the normovol-
emic hemodilution during surgery.
Normovolemic hemodilution is well described in the
surgical literature. It has been shown to result in a decrease
in the need for allogeneic blood products in the surgical
repair of both abdominal aortic aneurysms7 and in TAAs.8
Its benefit is particularly noted when it is combined with
cell salvage.9,10 Cell salvage will recirculate red cells but not
coagulation factors, as the coagulation factors and platelets
are activated at the surgical site, thus leaving the salvaged
coagulation factors unusable. In addition, if mixed with
hemodilluted coagulation factors, these factors will become
activated, thus leaving them unusable. Therefore, the
whole blood acquired during hemodillution was separated
into components. The five units were pulled off and frac-
tionated into their components so that adequate amounts
of plasma and platelets were available for correction of any
coagulation defect at the end of surgery. Suprisingly, he-
modillution has been theorized to induce a hypercoaguable
state, but the combined affects of this and hepatic ischemia
have not been ellucidated.11
The key factor in perioperative plasma and platelet
pheresis is to have adequate amounts of plasma and plate-
lets to correct a coagulation defect.12 Recommendation for
fresh autologous plasma is 10 mL/kg because fresh alloge-
neic plasma is used. The target yield for fresh autologous
platelet harvest is one unit per 15 kg of patient body weight.
The direct draw method (used in this patient) typically
yields 1.5 to 2.0 units per cycle, depending on baseline
patient values. Red cells are continuously given back during
Depiction of typical sequestration and cell salvage system used in this patient. Sequestration disposables are connected
directly into patient so that there is continuous fluid path from blood product to patient.
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the fractionation to maintain circulating volume, and some
are saved. Because the patient is hemodiluted, the patient
becomes increasingly anemic. As the anemia increases,
more blood needs to be pulled off to get a enough platelets.
The amount of blood pulled off is deceptively large because
some of it is given back during the process.
In this patient, the ability to withdraw 2700 mL at the
start of the operation, with its subsequent fractionation into
packed red cells, platelet-rich plasma, and platelet-poor
plasma, allowed for reinfusion of these products at the end
of the operation, when hemostasis was vital. In addition, it
preserved total red cell mass by decreasing the hematocrit
of blood that was lost.
The Jehovah’s Witness patient presents a special chal-
lenge to the surgeon. Recent advances in blood conserva-
tion, however, have made it safer to undertake major vas-
cular surgery in these patients. Such measures should be
considered in any patient who is in need of a major vascular
procedure and who has religious objections to allogeneic
blood transfusion.
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